对于社保基金，本期较上一季未再披露的社保基金共计1个，即招商基金管理有限公司-社保基金1903组 合。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 2025年10月29日，克明食品(002661.SZ)发布2025年第三季报。截至2025年10月28日，共有5个机构投资 者披露持有克明食品A股股份，合计持股量达1.16亿股，占克明食品总股本的34.79%。其中，机构投资 者包括湖南克明食品集团有限公司、南县中香泰食品有限公司、南县中辉泰食品有限公司、湖南省财信 资产管理有限公司、中国民生银行股份有限公司-金元顺安元启灵活配置混合型证券投资基金，机构投 资者合计持股比例达34.79%。相较于上一季度，机构持股比例合计下跌了0.62个百分点。 公募基金方面，本期较上一季度新披露的公募基金共计1个，即金元顺安元启灵活配置混合。本期较上 一季未再披露的公募基金共计116个，主要包括南华丰汇混合A、国泰海通中证500指数增强A、国泰海 通中证1000指数增强A、国金量化多因子A、国泰海通中证A500指数增强A等。 ...

2025年10月29日，昇辉科技(300423.SZ)发布2025年第三季报。截至2025年10月28日，共有3个机构投资 者披露持有昇辉科技A股股份，合计持股量达347.63万股，占昇辉科技总股本的0.70%。其中，机构投 资者包括中国民生银行股份有限公司-金元顺安元启灵活配置混合型证券投资基金、MORGAN STANLEY & CO. INTERNATIONAL PLC.、同泰沪深300量化增强A，机构投资者合计持股比例达 0.70%。相较于上一季度，机构持股比例合计上涨了0.41个百分点。 公募基金方面，本期较上一季度新披露的公募基金共计2个，包括金元顺安元启灵活配置混合、同泰沪 深300量化增强A。本期较上一季未再披露的公募基金共计19个，主要包括国金量化多因子A、国金量化 精选A、易方达中证万得并购重组指数(LOF)、中证2000、海富通创业板增强C等。 ...

Core Insights - 中旗股份 (300575.SZ) reported its Q3 2025 results, revealing that as of October 23, 2025, six institutional investors held a total of 16.8793 million A-shares, accounting for 3.54% of the total share capital, with an increase of 0.52 percentage points from the previous quarter [1] Institutional Holdings - The institutional investors include various entities such as China Foreign Economic and Trade Trust Co., Ltd., Guotai Junan Securities, and others, collectively increasing their holdings [1] - One new public fund was disclosed this period, while 11 public funds were not disclosed compared to the previous quarter, indicating a shift in public fund participation [1] Social Security Fund - The social security fund saw a slight increase in holdings, specifically from Guotai Fund Management Co., Ltd. - Social Security Fund 421 Combination [2] Foreign Investment - There were no new disclosures from foreign institutions this quarter, with Barclays Bank PLC being the only foreign entity not reported in the current period [3]

Core Insights - Xinguang Pharmaceutical (300519.SZ) released its semi-annual report for 2025, indicating a total of 29.12 million shares held by institutional investors, representing 18.20% of the company's total equity [1] Institutional Holdings - As of August 25, 2025, four institutional investors disclosed their holdings in Xinguang Pharmaceutical, with a combined ownership of 29.12 million shares, an increase of 0.75 percentage points from the previous quarter [1] - The institutional investors include Shengzhou Huanfeng Investment Co., Ltd., China Minsheng Bank Co., Ltd. - Jinyuan Shun'an Flexible Allocation Mixed Securities Investment Fund, BARCLAYS BANK PLC, and China Construction Bank Co., Ltd. - Nuoan Multi-Strategy Equity Fund [1] Public Fund Activity - One public fund, Jinyuan Shun'an Flexible Allocation Mixed Fund, increased its holdings compared to the previous period, while a new public fund, Nuoan Multi-Strategy Mixed A, was disclosed this quarter [1] - One public fund, Huatai-PineBridge CSI Traditional Chinese Medicine ETF, was not disclosed in this quarter compared to the previous one [1] Foreign Investment - One new foreign institutional investor, BARCLAYS BANK PLC, disclosed its holdings in Xinguang Pharmaceutical this quarter [1]